Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors

Liver Transpl. 2007 Mar;13(3):327-33. doi: 10.1002/lt.21056.

Abstract

Liver transplantation can be a therapeutic option for individual patients with neuroendocrine tumors metastatic only to the liver. In this consecutive series of 15 patients (5 multivisceral and 10 orthotopic liver transplantations) with well-differentiated carcinoids, or endocrine pancreatic tumors, we allowed higher proliferation rate (Ki67 <10%), large tumor burden, and higher age than previous studies. Liver transplantation offered good relief of symptoms, long disease-free intervals, and potential cure in individual patients. The survival of grafts and patients compared well with transplantation for benign disease. The overall 5-year survival was 90%. The recurrence-free survival of both multivisceral and liver transplantation related to the time after transplantation (about 20% at 5 years) despite inclusion of patients with higher risk. In conclusion, the critical prognosticators for long-term outcome still remain to be defined. The experience with multivisceral transplantation for patients with endocrine tumors of the pancreatic head is still limited.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Duodenum / transplantation
  • Female
  • Humans
  • Immunosuppression Therapy / methods
  • Liver Neoplasms / secondary*
  • Liver Neoplasms / surgery*
  • Liver Transplantation*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / prevention & control
  • Neuroendocrine Tumors / secondary*
  • Neuroendocrine Tumors / surgery*
  • Organ Transplantation*
  • Pancreas Transplantation
  • Pancreatic Neoplasms / pathology
  • Prognosis
  • Retrospective Studies
  • Stomach / transplantation
  • Survival Rate
  • Treatment Outcome